Skip to main content
SpringerLink
Log in

First-line therapy of acromegaly: A statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group

  • Manifesto
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000, 85: 526–9.

    CAS  PubMed  Google Scholar 

  2. Biochemical assessment and long-term monitoring in patients with acromegaly: Statement from a Joint Consensus Conference of The Growth Hormone Research Society and The Pituitary Society. J Clin Endocrinol Metab 2004, 89: 3099–102.

    Article  Google Scholar 

  3. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis and management. Endocr Rev 2004, 25: 102–52.

    Article  CAS  PubMed  Google Scholar 

  4. Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’. Eur J Endocrinol 2005, 152: 379–87.

    Article  CAS  PubMed  Google Scholar 

  5. Lissett CA, Peacey SR, Laing I, Tetlow L, Davis JR, Shalet SM. The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma. Clin Endocrinol (Oxf) 1998, 49: 653–7.

    Article  CAS  Google Scholar 

  6. Ahmed S, Elsheikh M, Stratton IM, Page RC, Adams CB, Wass JA. Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol (Oxf) 1999, 50: 561–7.

    Article  CAS  Google Scholar 

  7. Barker FG II, Klibanski A, Swearingen B. Trans-sphenoidal surgery for pituitary tumors in the United States 1996–2000: morbidity, mortality and the effects of hospital and surgeon volume. J Clin Endocrinol Metab 2003, 88: 4709–19.

    Article  CAS  PubMed  Google Scholar 

  8. Jezkova J, Marek J, Hana V, et al. Gamma knife radiosurgery for acromegaly—long-term experience. Clin Endocrinol (Oxf) 2006, 64: 588–95.

    Article  Google Scholar 

  9. Castinetti F, Taieb D, Kuhn JM, et al. Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. J Clin Endocrinol Metab 2005, 90: 4483–8.

    Article  CAS  PubMed  Google Scholar 

  10. Attanasio R, Epaminonda P, Motti E, et al. Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study. J Clin Endocrinol Metab 2003, 88: 3105–12.

    Article  CAS  PubMed  Google Scholar 

  11. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004, 89: 1613–7.

    Article  CAS  PubMed  Google Scholar 

  12. Kauppinen-Makelin R, Sane T, Reunanen A, et al. A nation-wide survey of mortality in acromegaly. J Clin Endocrinol Metab 2005, 90: 4081–6.

    Article  PubMed  Google Scholar 

  13. Minniti G, Traish D, Ashley S, Gonsalves A, Brada M. Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J Clin Endocrinol Metab 2005, 90: 800–4.

    Article  CAS  PubMed  Google Scholar 

  14. Melmed S, Casanueva F, Cavagnini F, et al. Consensus statement: medical management of acromegaly. Eur J Endocrinol 2005, 153: 737–40.

    Article  CAS  PubMed  Google Scholar 

  15. Cozzi R, Montini M, Attanasio R, et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumour shrinkage. J Clin Endocrinol Metab 2006, 91: 1397–403.

    Article  CAS  PubMed  Google Scholar 

  16. Colao A, Pivonello R, Auriemma RS, et al. Predictors of tumour shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 2006, 91: 2112–8.

    Article  CAS  PubMed  Google Scholar 

  17. Bevan JS. The antitumoural effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005, 90: 1856–63.

    Article  CAS  PubMed  Google Scholar 

  18. Melmed S, Sternberg R, Cook D, et al. A critical analysis of pituitary tumour shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 2005, 90: 4405–10.

    Article  CAS  PubMed  Google Scholar 

  19. Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002, 87: 3013–8.

    Article  CAS  PubMed  Google Scholar 

  20. Colao A, Ferone D, Lastoria S, et al. Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab 1996, 81: 2356–62.

    CAS  PubMed  Google Scholar 

  21. Colao A, Ferone D, Marzullo P, et al. Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 1997, 82: 518–23.

    Article  CAS  PubMed  Google Scholar 

  22. Freda PU, Reyes CM, Nuruzzaman AT, Sundeen RE, Khandji AG, Post KD. Cabergoline therapy of growth hormone and growth hormone/prolactin secreting pituitary tumours. Pituitary 2004, 7: 21–30.

    Article  CAS  PubMed  Google Scholar 

  23. Selvarajah D, Webster J, Ross R, Newell-Price J. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur J Endocrinol 2005, 152: 569–74.

    Article  CAS  PubMed  Google Scholar 

  24. Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf) 2004, 61: 209–15.

    Article  CAS  Google Scholar 

  25. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 2002, 23: 623–46.

    Article  CAS  PubMed  Google Scholar 

  26. Colao A, Pivonello R, Auriemma RS, et al. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumour mass, hypertension and glucose tolerance. Eur J Endocrinol 2006, 154: 467–77.

    Article  CAS  PubMed  Google Scholar 

  27. Barkan AL, Burman P, Clemmons DR, et al. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab 2005, 90: 5684–91.

    Article  CAS  PubMed  Google Scholar 

  28. Biering H, Saller B, Bauditz J, et al. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. Eur J Endocrinol 2006, 154: 213–20.

    Article  CAS  PubMed  Google Scholar 

  29. Feenstra J, de Herder WW, ten Have SM, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005, 365: 1644–6.

    Article  CAS  PubMed  Google Scholar 

  30. Petrossians P, Borges-Martins L, Espinoza C, et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol 2005, 152: 61–6.

    Article  CAS  PubMed  Google Scholar 

  31. Colao A, Attanasio R, Pivonello R, et al. Partial surgical removal of growth hormone-secreting pituitary tumours enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2006, 91: 85–92.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular and Clinical Endocrinology and Oncology, University “Federico II” of Naples, Naples, Italy

    A. Colao MD

  2. Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy

    E. Martino

  3. Department of Neurological Sciences, University “Federico II” of Naples, Naples, Italy

    P. Cappabianca

  4. Endocrine Unit, Ospedale Niguarda, Milan, Italy

    R. Cozzi

  5. U.O. Neurochirurgia Endocrina, University of Padua, Padua, Italy

    M. Scanarini

  6. Department of Internal Medicine, University of Turin, Turin, Italy

    E. Ghigo

Authors
  1. A. Colao MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Martino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Cappabianca
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Cozzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Scanarini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. Ghigo
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group

Corresponding author

Correspondence to A. Colao MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Colao, A., Martino, E., Cappabianca, P. et al. First-line therapy of acromegaly: A statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group. J Endocrinol Invest 29, 1017–1020 (2006). https://doi.org/10.1007/BF03349217

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03349217

Key-words

Search

Navigation